iwCLL 2019 | Predicting TLS in venetoclax-treated CLL patients

Anthony Mato

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, talks about predicting tumor lysis syndrome (TLS) in venetoclax-treated chronic lymphocytic leukemia (CLL) patients. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video